Kytril (granisetron), marketed as Kevatril in Germany and, in patch form, as Sancuso, is licensed to prevent chemotherapy- and radiotherapy-induced nausea and vomiting, and generic granisetron injection and tablets now sit alongside the originator across most of the markets M Care serves.
Kytril (granisetron), originated by SmithKline Beecham and marketed under that name across most of the EU and the UK, and as Kevatril in Germany specifically, is a selective 5-HT3 (serotonin) receptor antagonist used to prevent nausea and vomiting from emetogenic chemotherapy, radiotherapy and surgery, with the once-applied Sancuso transdermal patch covering multi-day regimens. M Care Exports is a merchant exporter: we source Kytril/Kevatril, the Sancuso patch and FDA-approved generic granisetron injection and tablets through licensed Indian distribution and manufacturing channels and dispatch on quote, not from our own manufacturing.
Granisetron exporter and bulk supplier from India.
For hospital oncology pharmacy, wholesaler and tender-desk orders, M Care quotes granisetron against buyer specification: injection (1 mg/mL or the paediatric-strength 0.1 mg/mL), 1 mg or 2 mg film-coated tablets, or the Sancuso 3.1 mg/24-hour patch, brand or a licensed generic line, drawn from multiple WHO-GMP partner sites on the M Care roster. Because granisetron injection has appeared on the FDA drug shortage list, we confirm current manufacturer availability and destination-market registration status at enquiry before we build the quote, then align CTD/eCTD or country-specific dossier paperwork to the destination regulator's requirements.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Selective 5-HT3 (serotonin) receptor antagonist; antiemetic, sourced and documented for export.
Granisetron is a selective 5-HT3 (serotonin) receptor antagonist. It blocks serotonin binding at vagal afferent and central chemoreceptor-trigger-zone sites, which interrupts the reflex that drives emetogenic chemotherapy- and radiotherapy-induced nausea and vomiting, without the dopamine-blocking side effects seen in older antiemetic classes. Kytril's FDA-labelled indications are prevention of nausea and vomiting from initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin, and prevention and treatment of postoperative nausea and vomiting in adults; the UK/EU SmPC for Kytril tablets extends to prevention of delayed nausea and vomiting after chemotherapy and radiotherapy. It is not indicated for chronic or unrelated nausea.
Active ingredient
granisetron hydrochloride (injection and tablets); granisetron base (transdermal patch). Selective 5-HT3 (serotonin) receptor antagonist; antiemetic.
Forms and strengths
1 mg/mL injection (free base); 0.1 mg/mL injection, paediatric-strength (free base); 1 mg film-coated tablet; 2 mg film-coated tablet; 3.1 mg/24 hours transdermal patch.
Indications
Selective 5-HT3 receptor antagonist indicated for prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and for prevention and treatment of postoperative nausea and vomiting, supplied as injection, tablets and, for multi-day chemotherapy regimens, the Sancuso transdermal patch.
Administration
Intravenous, Oral, Transdermal. Solution for injection, film-coated tablet, and transdermal patch (Sancuso).
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for granisetron are chiefly hospital oncology and day-case chemotherapy pharmacists standardising a 5-HT3 antiemetic protocol, anaesthesia and day-surgery units stocking a postoperative nausea and vomiting line, national and regional MoH tender desks running oncology supportive-care procurement lists, licensed pharmaceutical wholesalers and importers serving cancer centres, and NGO or foundation programmes supporting chemotherapy-access initiatives where supportive-care medicines are bundled into the same tender as the cytotoxic agent itself.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on granisetron.
Chemotherapy-prophylaxis dosing is weight-based, not fixed: 10 mcg/kg IV within 30 minutes before the start of chemotherapy, the same regimen used in paediatric patients aged 2 to 16. Serotonin syndrome has been reported with 5-HT3 antagonists, particularly alongside other serotonergic medicines such as SSRIs, SNRIs and tramadol, so medicines reconciliation should check for these before dispensing. Granisetron can prolong the QT interval and warrants caution in patients with pre-existing arrhythmia or cardiac-conduction disorders. The Sancuso patch needs its own counselling: applied to the upper outer arm 24 to 48 hours before chemotherapy, worn for up to seven days, kept away from heat sources and covered from direct sunlight during wear and for ten days after removal.
The documentation pack a regulator actually asks for.
Granisetron injection and tablets are room-temperature products; the injection is stored at 20-25C, protected from light and not frozen, and Kytril tablets are stored below 25C, so none of the three presentations needs the validated cold-chain lanes M Care runs for biologics. What buyers need instead is confirmation of which presentation and strength a tender specifies, since injection, tablet and patch carry separate registration files in most destination markets, alongside the usual batch-level certificate of analysis, CDSCO export documentation and CTD/eCTD dossier support for markets such as MHRA, SFDA, MOHAP, NAFDAC, PPB or SAHPRA that require local registration before import. Granisetron is not on the WHO Model List of Essential Medicines; the current EML lists ondansetron as its core 5-HT3 antiemetic, with granisetron named only as a therapeutic alternative under the same ATC group, which tender desks running an EML-aligned formulary should factor into procurement priority. On brand versus generic: Kytril is the originator product from SmithKline Beecham, marketed under that name across most of the EU and UK and as Kevatril in Germany specifically. The Sancuso patch's US marketing rights passed from Kyowa Kirin to its current holder, Cumberland Pharmaceuticals, in January 2022. FDA-approved generic granisetron injection is separately registered from multiple manufacturers, including Akorn, Fresenius Kabi and Hikma, and the FDA drug shortage database has listed granisetron hydrochloride injection as currently in shortage, which is a live reason tender desks and hospital pharmacies keep a secondary export source on file for this molecule specifically.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside granisetron.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for granisetron.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Granisetron supply, the specific questions.
Does a generic version of Kytril exist?
Yes. FDA-approved generic granisetron injection is registered and marketed in the US from several manufacturers, including Akorn, Fresenius Kabi and Hikma, and generic granisetron tablets are also separately licensed in the UK. Registration status for generic granisetron varies by destination country, so M Care checks local approval before quoting brand or generic against a specific tender.
Can M Care supply Kytril, Kevatril or Sancuso to our market?
Yes, on an import basis, where the product is registered in your market. We source Kytril/Kevatril and the Sancuso patch through licensed Indian distribution channels and dispatch against your import authorisation and destination-market registration requirements. We do not manufacture any of the three ourselves.
What strengths and dosage forms of granisetron does M Care supply?
1 mg/mL injection and a paediatric-strength 0.1 mg/mL presentation, 1 mg and 2 mg film-coated tablets, and the Sancuso 3.1 mg/24-hour transdermal patch. Tell us your protocol, indication mix and preferred presentation and we quote accordingly.
Is granisetron injection currently affected by supply shortages?
Yes. The FDA drug shortage database lists granisetron hydrochloride injection as currently in shortage. This is one reason hospital pharmacies and tender desks in our GCC and African markets keep a secondary export source on file for the injectable presentation specifically, rather than relying on a single line.
Is granisetron on the WHO Essential Medicines List?
No. The WHO Model List names ondansetron as its core 5-HT3 antiemetic and lists granisetron only as a therapeutic alternative under the same ATC group. Formulary desks running an EML-aligned tender should factor that into how they prioritise a granisetron line against ondansetron.
Does granisetron need cold-chain shipping?
No. The injection is stored at 20-25C protected from light, and Kytril tablets are stored below 25C; the Sancuso patch is also stored at controlled room temperature. None of the three presentations needs the validated cold-chain lanes M Care runs for biologics.
What documentation does M Care provide with a granisetron shipment?
Batch-level certificate of analysis, CDSCO export documentation from the Indian side, and CTD/eCTD-aligned dossier support where the destination regulator requires local registration, plus confirmation of exactly which presentation, strength and brand-or-generic status a shipment contains.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-13.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.